Press Releases
Press Releases
Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care
Roche announced that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark. Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S. FDA.
The SARS-CoV-2 Rapid Antigen Test is...
Press Releases
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it is investing $50 million to install an additional high-speed vial filling line...
Press Releases
Novartis, AMSP collaborate to facilitate supply of COVID-19 related medicines to AU member states & Caricom countries
Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.
The AMSP...
Press Releases
Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it has signed two agreements in Hainan, China with PT Bio Farma, a leading biopharmaceutical company in Indonesia, for the supply, local production and technology licensing in...
Press Releases
Biocon Biologics and Mylan Announce Launch of Semglee in the U.S. to Expand Access for Patients Living with Diabetes
Biocon Biologics India Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd., and Mylan N.V. announced the U.S. launch of Semglee™ (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control...
Press Releases
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
Gilead Sciences, Inc. announced an agreement with Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.
JTX-1811 is a monoclonal antibody designed to selectively...
Press Releases
Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.